It indicates that exosomal mutant KRAS DNA leads to this conversion, and it is further confirmed by the enrichment of FoxP3+ Tregs in tumor tissues from mutant KRAS patients, compared to the WT KRAS controls [69]. The gene discussed is FOXP3; the disease is neoplasm.